Vincent Ossipow

Sectoral Asset Management, Inc. (Switzerland) (Sectoral) is the Swiss subsidiary of Sectoral Asset Management, Inc. in Canada. Established in 2005, Sectoral is located in Geneva and has cooperated with Pictet Bank since the firm was founded. The firm is a healthcare equity specialist. They manage traditional portfolios as well as hedge funds, and sub-advise sector funds for third-party asset managers worldwide. They also manage discretionary portfolios for high-net worth individuals. The firm's clients include global pension plans, private banks and family offices. They also provide sub-advisory for institutional investors in Europe, North America and Asia.

Covalence SA is an independent Swiss investment research firm which was co-founded by Antoine Mach and Marc Rochat in 2001. Headquartered in Carouge, the firm delivers data and research to corporates, academics and non-profits relying on its EthicalQuote reputation index. Their services includes ESG ratings, ESG news data, portfolio advisory, and impact stories, and support sustainable and responsible investment, ESG integration and impact investing strategies. Covalence is a socially responsible investor and signatory to the UN Principles for Responsible Investment (UNPRI).

Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US.

Pictet Bank & Trust Ltd. (Private Banking) (Pictet Bank & Trust-PB) is the private banking arm of Pictet Bank & Trust Ltd., an offshore bank headquartered in Nassau, Bahamas. The firm was founded in 1978 and is a subsidiary of Banque Pictet & Cie SA, a Swiss private bank which specializes in asset and wealth management. Pictet Bank & Trust-PB provides wealth management and asset servicing for private clients.

eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium.

Andrew Alliance SA develops liquid handling solutions. Its product, Andrew, is a novel liquid handling robot designed for pipetting process. The firm's products include Andrew models, consumable dominos, protocol design, and enabling accessories. The company was founded by Piero Zucchelli, Giorgio Horak, and Antoine Jordan in March 2011 and is headquartered in Vernier, Switzerland.

Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany.

FoRx Therapeutics AG operates as a biotechnology company developing a new generation of cancer drugs focusing on novel deoxyribonucleic acid (DNA) Replication Stress pathways activated in cancer. The firm also provides research and development services. The company was founded by Thanos Halazonetis and Sotirios K. Sotiriou in 2019 and is headquartered in Basel, Switzerland.

Omega Alpha SPAC is a blank check company. Its purposes effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Otello Stampacchia, Michelle Doig, Francesco Draetta and Vincent Ossipow on October 26, 2020 and is headquartered in Boston, MA.

Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya.